COVID cash is buying an oncology reset
- BioNTech still makes most revenue from COMIRNATY, its COVID-19 vaccine with Pfizer.
- 2026 revenue guidance is €2.0 billion to €2.3 billion, with lower COVID-19 sales partly offset by BMS revenue.
- The BMS deal for pumitamig brings $3.5 billion of noncontingent cash through 2028.
- Oncology now takes about 90% of current R&D spend, so trial results matter more than vaccine headlines.
- The risk is execution: iNeST missed in advanced melanoma, BNT323 was delayed, and the founders plan to step down by the end of 2026.
A funded but hard pivot
The bull case is simple. BioNTech turned the COVID-19 vaccine boom into a huge funding base, then aimed that cash at cancer. The company ended 2025 with about €17.2 billion in cash, cash equivalents, and security investments. That gives it time to run large oncology trials without needing to raise money in a weak market.
The biggest new support is the Bristol Myers Squibb partnership for pumitamig, also called BNT327. BMS paid $1.5 billion upfront, and BioNTech expects $2.0 billion more in noncontingent anniversary payments through 2028. The two companies will share development, manufacturing, profits, and losses on a 50:50 basis.
The bear case is that cash does not make drugs work. iNeST, the individualized mRNA cancer vaccine platform, missed its progression-free survival endpoint in advanced melanoma. Progression-free survival means how long patients live before the cancer gets worse. BioNTech is now focusing iNeST more on adjuvant settings, where treatment happens after surgery or other therapy and disease may be slower moving.
The setup is mixed, which matches Finn's cautious score. BioNTech has money, partners, and many shots on goal. It also has falling COVID-19 revenue, delayed regulatory timing for BNT323, legal cost overhangs, and a founder-led leadership handoff planned by the end of 2026.
Vaccine cash, cancer spend
BioNTech makes commercial money mainly from COMIRNATY, its COVID-19 vaccine sold with Pfizer. In 2025, COVID-19 vaccine revenue was €1.995 billion out of €2.870 billion total revenue. The vaccine market is now seasonal and smaller than during the pandemic, so this cash cow is declining.
The company is spending that vaccine cash on a multi-technology cancer pipeline. It started as an mRNA leader, but it now also works on bispecific antibodies, antibody-drug conjugates, and other immunotherapies. Antibody-drug conjugates are targeted cancer drugs that link an antibody to a cell-killing payload.
The BMS deal changes the funding math. BioNTech recognized €613.0 million of out-licensing revenue in 2025 from the pumitamig partnership, while part of the upfront payment was deferred for future recognition. That helps bridge the gap as COVID-19 sales shrink.
The model breaks if late-stage cancer trials fail, regulators ask for more data, or manufacturing cannot scale. BioNTech reports as one operating segment, but economically the company is moving from one large commercial vaccine product toward several still-unproven oncology products.
What BioNTech is betting on
COMIRNATY
COMIRNATY is the COVID-19 vaccine sold with Pfizer. It still funds much of the company, but 2026 guidance assumes lower COVID-19 vaccine revenue.
Pumitamig, BNT327
Pumitamig is a PD-L1 and VEGF bispecific antibody, meaning one drug is designed to hit two cancer-related targets. BioNTech shares global development and commercialization with BMS.
BNT323
BNT323 is a HER2 antibody-drug conjugate being prepared for a possible BLA in second-line endometrial cancer. The filing moved into 2026 after the FDA asked for more analysis and follow-up data.
iNeST
iNeST is BioNTech's individualized mRNA cancer vaccine platform. After missing in advanced melanoma, the strategy is focused more on adjuvant disease, where the immune response has more time to build.
FixVac
FixVac is an off-the-shelf mRNA cancer vaccine approach. BNT111 met a Phase 2 primary endpoint in melanoma, but it still needs later proof before it can become a product.
Infectious disease programs
BioNTech also works on vaccines and therapeutics for infectious diseases. These programs matter, but the current investment story is mostly about oncology.
One segment, three revenue buckets
BioNTech reports one operating and reporting segment. The mix shown here uses the fiscal 2025 revenue categories disclosed in the 2025 Form 20-F: COVID-19 vaccine revenue, out-licensing revenue, and other revenue.
What could go wrong
COVID revenue keeps shrinking
High impact · High oddsCOVID-19 vaccine revenue fell from €2.432 billion in 2024 to €1.995 billion in 2025. Management also guided 2026 total revenue to €2.0 billion to €2.3 billion and said COVID-19 vaccine revenue should be lower. If seasonal demand weakens faster than expected, the cash bridge to oncology gets thinner.
iNeST works too slowly in advanced cancer
Medium impact · Medium oddsThe individualized mRNA vaccine iNeST missed its progression-free survival endpoint in advanced melanoma. BioNTech has said the immune response may take six to eight weeks to develop, which can be too slow for fast-growing metastatic disease. The platform may still work better after surgery or earlier treatment, but that narrows the near-term market.
BNT323 faces FDA and supply risk
High impact · Medium oddsBioNTech planned a BLA for BNT323 in endometrial cancer, but the submission moved into 2026 after FDA discussions about additional data needs. The internal risk is bigger because manufacturing has been supplied by a China-based CDMO while BioNTech works to diversify supply. A delay or supply problem could push out the first oncology launch.
Pumitamig does not justify the BMS push
High impact · Medium oddsThe BMS partnership brings large noncontingent cash, but the drug still has to succeed in broad Phase 3 testing. BioNTech and BMS are sharing costs, profits, and losses, so failure would hurt both the pipeline story and future economics. The market may give little credit until randomized data are clear.
Leadership handoff breaks focus
Medium impact · Medium oddsCo-founders Ugur Sahin and Ozlem Tureci plan to transition by the end of 2026 to lead a new independent mRNA company. BioNTech says its Supervisory Board has started an executive search. The risk is not that the company lacks science, but that a hard oncology pivot loses continuity at the top.
Legal and patent costs keep draining cash
Medium impact · Medium oddsBioNTech recorded large legal and settlement expenses in recent years, including expenses linked to contractual disputes and patent matters. These costs do not decide whether the cancer drugs work, but they can pressure earnings while revenue is falling. More disputes would make the transition period more expensive.
In one breath
Is BioNTech still mainly a COVID vaccine company?
Commercially, yes. Most 2025 revenue came from COVID-19 vaccine sales. Strategically, the company is trying to become an oncology company, with about 90% of current R&D spend going to oncology.
Why does the BMS deal matter for BioNTech?
The BMS deal helps pay for a much larger pumitamig trial program. It gives BioNTech $1.5 billion upfront and $2.0 billion in noncontingent anniversary payments through 2028, while sharing future costs and economics.
What is the next big BioNTech catalyst?
Investors should watch the 2026 BNT323 filing path and randomized data from pumitamig studies. Leadership succession is also important because the founding CEO and CMO plan to step down by the end of 2026.
Does BioNTech have enough cash to fund the pivot?
BioNTech ended 2025 with about €17.2 billion in cash, cash equivalents, and security investments. That is a strong cushion, but it does not remove clinical, regulatory, or execution risk.